We’ve recently updated our valuation analysis.

MariMed Valuation

Is MRMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MRMD?

Other financial metrics that can be useful for relative valuation.

MRMD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.9x
Enterprise Value/EBITDA10.2x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does MRMD's PE Ratio compare to its peers?

The above table shows the PE ratio for MRMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average10.1x
BTMD biote
2.2x-13.0%US$232.2m
SLGL Sol-Gel Technologies
22.1x61.0%US$108.0m
PRPH ProPhase Labs
5.4x-73.0%US$169.8m
SHWZ Medicine Man Technologies
10.8xn/aUS$98.0m
MRMD MariMed
83xn/aUS$183.2m

Price-To-Earnings vs Peers: MRMD is expensive based on its Price-To-Earnings Ratio (83x) compared to the peer average (10.1x).


Price to Earnings Ratio vs Industry

How does MRMD's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.4%
n/an/an/a

Price-To-Earnings vs Industry: MRMD is expensive based on its Price-To-Earnings Ratio (83x) compared to the US Pharmaceuticals industry average (17x)


Price to Earnings Ratio vs Fair Ratio

What is MRMD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MRMD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio83x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MRMD's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of MRMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MRMD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MRMD's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MRMD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.54
US$0.97
+80.7%
12.8%US$1.10US$0.85n/a2
Nov ’23US$0.54
US$1.05
+94.4%
19.0%US$1.25US$0.85n/a2
Oct ’23US$0.43
US$1.25
+188.5%
0%US$1.25US$1.25n/a1
Sep ’23US$0.58
US$1.25
+113.7%
0%US$1.25US$1.25n/a1
Aug ’23US$0.70
US$1.50
+114.9%
0%US$1.50US$1.50n/a1
Jul ’23US$0.48
US$1.50
+212.5%
0%US$1.50US$1.50n/a1
Jun ’23US$0.62
US$1.50
+141.9%
0%US$1.50US$1.50n/a1
May ’23US$0.64
US$1.50
+134.4%
0%US$1.50US$1.50n/a1
Apr ’23US$0.71
US$1.88
+163.0%
20.0%US$2.25US$1.50n/a2
Mar ’23US$0.75
US$2.25
+201.4%
0%US$2.25US$2.25n/a1
Feb ’23US$0.83
US$2.25
+169.5%
0%US$2.25US$2.25n/a1
Jan ’23US$0.86
US$2.25
+160.1%
0%US$2.25US$2.25n/a1
Dec ’22US$0.69
US$2.25
+224.4%
0%US$2.25US$2.25US$0.541
Nov ’22US$0.81
US$2.25
+177.8%
0%US$2.25US$2.25US$0.541
Oct ’22US$0.90
US$2.25
+150.4%
0%US$2.25US$2.25US$0.431

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies